What is the Worldcom Healthcare Monitor Pharmaceuticals 2025-2026?

It is a study by the Worldcom Public Relations Group — a global network of roughly 2,000 communications professionals across 45 countries — analyzing how ten of the largest pharmaceutical companies are represented inside AI-generated answers from ChatGPT, Gemini, Perplexity, Claude, and Google's AI Overviews. Now in its fifth edition, the 2025-2026 report drops the old scoreboard for a diagnostic approach: not who ranks first, but why some companies are represented more effectively than others.

Are large pharmaceutical companies visible in AI search engines?

Unevenly. The report found that visibility across the ten companies is not a mirror of brand size or marketing spend — some of the best-resourced companies in the world show real gaps in how AI systems surface and describe them. Presence, prominence, sentiment, and source authority vary widely from company to company.

Why do big pharma companies struggle with AI visibility despite large budgets?

Because AI systems assign authority differently than search engines do. They lean heavily on neutral, institutional, evidence-based sources — government health agencies, peer-reviewed literature, academic institutions — and apply a trust gradient to corporate domains. A large communications budget spent on an owned website does not overcome that gradient. It is a structural problem, not a spending problem.

What does the report mean for mid-cap and clinical-stage biopharma?

If the largest companies in the industry are exposed, smaller and clinical-stage companies — with thinner third-party coverage and less scientific citation — are more exposed, not less. The same forces apply, with less of an authority cushion to absorb them.

How can a biopharma company see how AI describes it?

Run the questions an investor, analyst, physician, or patient would ask across the major AI platforms and compare the answers to the company's own disclosures and the scientific record. A Narrative Drift Scan does this systematically and shows where the AI-generated narrative diverges from reality.

Narrative Intelligence

The World's Biggest Pharma Companies Are Losing the AI Narrative

August 3, 2026•6 min read•Michael Etheredge, VP of Product Development

Michael Etheredge is VP of Product Development at QuestionFuel, where he leads how the firm measures and corrects the way AI answer engines describe companies. He was featured by the Southern Economic Development Council on how AI is changing the way companies research communities and regions.

If you assumed the biggest names in pharma have AI visibility handled, a new report says otherwise. The Worldcom Public Relations Group's Healthcare Monitor Pharmaceuticals 2025-2026 benchmarked ten of the largest pharmaceutical companies — AbbVie, AstraZeneca, Bristol Myers Squibb, GSK, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Roche, and Sanofi — on how they show up inside AI-generated answers. The finding that matters: even companies with vast communications budgets and full IR and PR teams are being represented inconsistently, and sometimes barely at all, in the AI answers their stakeholders now rely on. This is not an under-resourced-company problem. It is a structural one — which means it applies to your company too.

Key takeaways

A new Worldcom study found even the ten largest pharma companies are represented unevenly in AI answers — AI visibility does not track brand size or budget.
Prominence, accuracy, and sentiment are independent: a company can be highly visible and poorly framed, or barely visible and favorably framed.
AI draws 51% of its pharmaceutical citations from nih.gov and only ~1-2% from even the strongest corporate websites — your owned site is not the primary input to your AI narrative.
Smaller and clinical-stage biopharma are more exposed than big pharma, not less, because they have less third-party corroboration to fall back on.
Fixing it requires a distributed authority model — entity clarity, structured citable content, and earned scientific and media references — not just a better website.

A diagnostic, not a scoreboard

The fifth edition of the Monitor deliberately moved away from ranking companies on a point system. Instead it examines why some pharmaceutical companies are represented more effectively than others across ChatGPT, Gemini, Perplexity, Claude, and Google's AI Overviews. That shift matters, because the interesting story in AI visibility is never a single number — it is the gap between how prominent a company is, how accurately it is described, and which sources the AI trusts when it answers.

Visibility and accuracy are not the same thing

The report makes that gap concrete. Pfizer led on awareness and share of voice, appearing most often across the tested prompts, with a generative-visibility awareness score of 5.3%. But prominence was not the whole picture. AbbVie, despite lower overall awareness, tended to appear earlier in AI answers — a meaningful advantage, because the first companies named in a generated response carry disproportionate weight. And Bristol Myers Squibb posted the highest sentiment score of the ten, 8.6 out of 10, despite ranking near the bottom on awareness. In other words, showing up often and being described favorably are independent variables. A company can be everywhere and framed poorly, or barely visible and framed well. Measuring only whether you appear misses half the risk.

The NIH effect: AI doesn't trust your website

The most striking finding concerns where AI actually gets its pharmaceutical information. When these platforms answered health questions, they drew overwhelmingly from a single source: nih.gov, the National Institutes of Health, which accounted for 51% of all citations — more than thirty times the share of any single corporate domain. The best-performing corporate website, AbbVie's, captured just 1.8%, followed by Pfizer at 1.5% and Novartis at 1.3%. Every other corporate domain received a fraction of a percentage point.

This is the heart of it. AI systems prefer sources that are neutral, evidence-based, and institutionally credible, and they apply a trust gradient to anything a company says about itself. Your website is not the primary input to your AI narrative — the broader information landscape is. That is exactly why a well-funded corporate site, on its own, cannot fix a weak AI presence.

Why your company is more exposed than Pfizer

Here is the uncomfortable extension the report implies. If Pfizer, with its enormous content ecosystem, captures only 1.5% of citations against the NIH's 51%, a mid-cap or clinical-stage biopharma with a single lead asset and thin third-party coverage is starting from far behind. And the stakes are rising fast: in G2's March 2026 "Answer Economy" survey of more than a thousand B2B software buyers, 51% said they now begin research in an AI chatbot more often than in Google — up from 29% a year earlier. The behavior is not confined to software buyers. The investors, analysts, physicians, and patients researching your asset increasingly start the same way, and they are forming an impression before they ever reach your site.

What actually moves the needle

The report's prescription aligns with what narrative intelligence has argued all along: owned channels are necessary but not sufficient. AI visibility in healthcare depends on a distributed authority model — strong, structured proprietary content reinforced by an ecosystem of earned references, scientific citations, media coverage, and third-party validation. In practice that means three things: entity clarity, so AI consistently associates your company with the right therapeutic areas and assets; structured, citable content that directly answers the questions stakeholders ask, rather than generic corporate pages; and sustained investment in the earned sources AI actually trusts.

None of that starts without knowing where you stand today. If the largest pharmaceutical companies in the world are still treating AI visibility as an afterthought, the question worth asking is simple: what is AI currently saying about your company — and is it accurate?

Want to know what AI is currently saying about your company? Request a Narrative Drift Scan.

Sources: Worldcom Public Relations Group, Healthcare Monitor Pharmaceuticals 2025-2026 (worldcomgroup.com); G2, The Answer Economy: How AI Search Is Rewiring B2B Software Buying (March 2026).